H. Lundbeck A/S
HLUN-B.CO - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$43.27B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $43.27 Billion |
|---|---|
| Enterprise Value | $50.49 Billion |
| Annual dividend | $1.15 |
| Dividend yield | 2.11% |
| Earnings per Share | $3.22 |
| Beta | 0.24 |
| Outstanding Shares | 989,655,172 |
Return
| Return on Equity | 14.44% |
|---|---|
| Return on Assets | 7.36% |
| Return on Invested Capital | 13.52% |
Valuation & Multiples
| P/E Ratio | 13.94 |
|---|---|
| PEG | 74 |
| Price to Sales | 2.23 |
| Price to Book Ratio | 2.06 |
| Enterprise Value to Revenue | 1.97 |
| Enterprise Value to EBIT | 8.62 |
| Enterprise Value to Net Income | 13 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 0.35 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$1.11
Consensus analyst estimateRevenue Estimate
$6.22 B
Consensus analyst estimateNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$1.10
Consensus analyst estimateRevenue Estimate
$6.33 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About H. Lundbeck A/S
5,214 employees
CEO: Charl van Zyl
H. Lundbeck A/S operates as an international biopharmaceutical entity, focusing its efforts on the entire lifecycle of pharmaceutical products—from initial research and development to manufacturing and global sales. The firm primarily sp...